[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Jade Biosciences Inc (JBIO)

Jade Biosciences Inc (JBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,152,803
  • Shares Outstanding, K 49,360
  • Annual Sales, $ 0 K
  • Annual Income, $ -127,410 K
  • EBIT $ -154 M
  • EBITDA $ -154 M
  • 60-Month Beta 1.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.01

Options Overview Details

View History
  • Implied Volatility 158.68% (+8.01%)
  • Historical Volatility 89.00%
  • IV Percentile 29%
  • IV Rank 16.52%
  • IV High 485.44% on 09/15/25
  • IV Low 94.02% on 11/17/25
  • Expected Move (DTE 31) 0.00 (0.00%)
  • Put/Call Vol Ratio 14.00
  • Today's Volume 15
  • Volume Avg (30-Day) 12
  • Put/Call OI Ratio 9.30
  • Today's Open Interest 1,453
  • Open Int (30-Day) 1,771
  • Expected Range 21.94 to 21.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.61
  • Number of Estimates 4
  • High Estimate $-0.43
  • Low Estimate $-0.79
  • Prior Year $-0.86
  • Growth Rate Est. (year over year) +29.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.68 +1.29%
on 05/18/26
28.00 -21.57%
on 04/27/26
-0.89 (-3.89%)
since 04/17/26
3-Month
12.91 +70.10%
on 03/24/26
28.00 -21.57%
on 04/27/26
+7.50 (+51.87%)
since 02/18/26
52-Week
6.57 +234.50%
on 06/13/25
28.00 -21.57%
on 04/27/26
+14.61 (+198.98%)
since 05/16/25

Most Recent Stories

More News
JBIO's Phase One Whisper Number Already Assumes Perfect Execution Nobody's Earned Yet

Barchart Research What to Expect from JBIO Earnings JBIO Generated May 7, 2026 Current Price $24.22 EPS Estimate $$-0.52 Consensus Rating Strong Buy Average Move 3.06% JBIO's Phase One Whisper Number Already...

JBIO : 21.99 (-5.82%)
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Interim biomarker-rich Phase 1 data for JADE101 to be featured in an oral session at the 63rd European Renal Association Congress  Phase 2 trial of JADE101 in IgA nephropathy patients expected to...

JBIO : 21.99 (-5.82%)
2 Small-Cap Stocks With Big Potential to Buy Under $30

These under-$30 stocks are betting on innovative therapies that could unlock massive long-term value.

JBIO : 21.99 (-5.82%)
ARTV : 9.77 (-0.10%)
Jade Biosciences: Clinical Data Timeline Collides With Cash Burn Reality

Barchart Research What to Expect from JBIO Earnings JBIO Generated April 30, 2026 Current Price $24.34 EPS Estimate $$-0.52 Consensus Rating Strong Buy Average Move 3.06% Jade Biosciences: Clinical Data...

JBIO : 21.99 (-5.82%)
Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO and VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused...

JBIO : 21.99 (-5.82%)
Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer

SAN FRANCISCO and VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused...

JBIO : 21.99 (-5.82%)
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated...

JBIO : 21.99 (-5.82%)
Jade Biosciences to Participate in Upcoming Conferences

SAN FRANCISCO and VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies...

JBIO : 21.99 (-5.82%)
Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference

JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026  Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin...

JBIO : 21.99 (-5.82%)
Jade Biosciences Announces $45 Million Private Placement

SAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused...

JBIO : 21.99 (-5.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Jade Biosciences Inc. is focused on developing therapies to address critical unmet needs in autoimmune diseases. The company pipeline includes antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade Biosciences Inc., formerly known as Aerovate Therapeutics Inc.,...

See More

Key Turning Points

3rd Resistance Point 27.40
2nd Resistance Point 26.10
1st Resistance Point 24.73
Last Price 21.99
1st Support Level 22.06
2nd Support Level 20.76
3rd Support Level 19.39

See More

52-Week High 28.00
Last Price 21.99
Fibonacci 61.8% 19.81
Fibonacci 50% 17.28
Fibonacci 38.2% 14.75
52-Week Low 6.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.